Keros Therapeutics, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 24/100
What the filing says
Keros Therapeutics executed an employment agreement with Annita Tanini, effective August 4, 2026, formalizing her role as Corporate Controller, Vice President Finance, and interim principal financial officer and principal accounting officer. Base salary: $302,300/year; target annual bonus: 30% ($90,690); severance upon termination without cause or resignation for good reason: 6 months base salary + COBRA; in change-of-control scenario: 6 months base salary + 100% target bonus ($90,690) + 100% acceleration of unvested equity. The agreement supersedes her prior May 2019 offer letter and includes standard restrictive covenants.
Why this rating
Routine administrative formalization of existing interim role. No material financial commitment or strategic change; severance caps and salary are proportionate to company size ($453M market cap). Standard executive employment paperwork.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.